董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| ジョンマラガノア | 男 | Director and Executive Chairman of the Board | 64 | 252.56万美元 | 212.18 | 2026-09-24 |
| Ron Philip | 男 | Director | 52 | 25.60万美元 | 3.37 | 2026-09-24 |
| Saraswathy V. Nochur | 女 | Director | 65 | 25.50万美元 | 2.74 | 2026-09-24 |
| John Maraganore | 男 | Director and Executive Chairman of the Board | 63 | 未披露 | 未持股 | 2026-09-24 |
| Andrew Orth | 男 | Chief Executive Officer and Director and President | 56 | 67.71万美元 | 109.45 | 2026-09-24 |
| Barry Greene | 男 | Director | 63 | 未披露 | 未持股 | 2026-09-24 |
| Ron Philip | 男 | Director | 52 | 未披露 | 未持股 | 2026-09-24 |
| Robert Nelsen | 男 | Director | 63 | 未披露 | 3.12 | 2026-09-24 |
| Barry Greene | 男 | Director | 62 | 25.50万美元 | 3.12 | 2026-09-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Keith Regnante | 男 | Chief Financial Officer | 56 | 未披露 | 未持股 | 2026-09-24 |
| ジョンマラガノア | 男 | Director and Executive Chairman of the Board | 64 | 252.56万美元 | 212.18 | 2026-09-24 |
| Sebastian Trousil | 男 | Chief Operating Officer | 42 | 未披露 | 未持股 | 2026-09-24 |
| Andrew Orth | 男 | Chief Executive Officer and Director and President | 56 | 67.71万美元 | 109.45 | 2026-09-24 |
| Tracy Zimmermann | 女 | Chief Scientific Officer | 57 | 68.68万美元 | 26.96 | 2026-09-24 |
| Baisong Mei | 男 | Chief Medical Officer | 62 | 89.20万美元 | 23.47 | 2026-09-24 |
董事简历
中英对照 | 中文 | 英文- ジョンマラガノア
-
John Maraganore是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、Blackstone Life Sciences的高级顾问、杰富瑞金融服务的高级顾问以及RTW Investments，LP的执行合伙人，RTW Investments，LP均为一家投资和风险投资公司。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（纳斯达克：PROK）董事会任职。Maraganore博士分别获得了芝加哥大学的生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
John Maraganore one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago. - John Maraganore是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、Blackstone Life Sciences的高级顾问、杰富瑞金融服务的高级顾问以及RTW Investments，LP的执行合伙人，RTW Investments，LP均为一家投资和风险投资公司。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（纳斯达克：PROK）董事会任职。Maraganore博士分别获得了芝加哥大学的生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
- John Maraganore one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago.
- Ron Philip
-
Ron Philip，Philip先生自2026年2月起担任CREATE Medicines的执行主席，最近担任Orbital Therapeutics的首席执行官和董事会成员，该公司是一家专注于开发基于RNA的药物的生物技术公司，自2024年8月起至2025年12月被百时美施贵宝收购。在加入Orbital之前，从2017年5月到2024年8月，Philip先生曾在基因治疗公司星火治疗担任多个职务，最近担任首席执行官。Philip先生还曾于2009年11月至2016年10月在辉瑞担任多个职务。Philip先生还自2024年7月起担任City Therapeutics，Inc.的董事会成员，自2026年2月起担任CREATE Medicines的董事会成员，自2025年4月起担任Harmony Biosciences（NASDAQ：HRMY）的董事会成员，并为多家私营生物技术公司提供咨询服务。菲利普此前还曾在多个私营组织的董事会任职，包括宾夕法尼亚州生命科学、德雷塞尔大学自然科学院、Cure Duchenne和大费城商会。
Ron Philip has served as a member of City Therapeutics, Inc.'s board of directors since July 2024. Mr. Philip served as Chief Executive Officer and as a member of the board of directors of Orbital Therapeutics, Inc. ("Orbital"), a biopharmaceutical company focused on RNA based medicines, from August 2024 until its acquisition by Bristol Myers Squibb (NYSE: BMY) in December 2025. Prior to joining Orbital, Mr. Philip served in roles of increasing responsibility at Spark Therapeutics, Inc. (formerly Nasdaq: ONCE) from May 2017 to August 2024, most recently as Chief Executive Officer. Prior to joining Spark Therapeutics, Mr. Philip served in various roles at Pfizer Inc. (NYSE: PFE) from November 2009 to October 2016. Mr. Philip currently serves on the board of directors of Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), Avalo Therapeutics, Inc. (Nasdaq: AVTX) and serves as Executive Chair of CREATE Medicines, Inc. Mr. Philip received a B.S. in Computer Information Systems from Drexel University. - Ron Philip，Philip先生自2026年2月起担任CREATE Medicines的执行主席，最近担任Orbital Therapeutics的首席执行官和董事会成员，该公司是一家专注于开发基于RNA的药物的生物技术公司，自2024年8月起至2025年12月被百时美施贵宝收购。在加入Orbital之前，从2017年5月到2024年8月，Philip先生曾在基因治疗公司星火治疗担任多个职务，最近担任首席执行官。Philip先生还曾于2009年11月至2016年10月在辉瑞担任多个职务。Philip先生还自2024年7月起担任City Therapeutics，Inc.的董事会成员，自2026年2月起担任CREATE Medicines的董事会成员，自2025年4月起担任Harmony Biosciences（NASDAQ：HRMY）的董事会成员，并为多家私营生物技术公司提供咨询服务。菲利普此前还曾在多个私营组织的董事会任职，包括宾夕法尼亚州生命科学、德雷塞尔大学自然科学院、Cure Duchenne和大费城商会。
- Ron Philip has served as a member of City Therapeutics, Inc.'s board of directors since July 2024. Mr. Philip served as Chief Executive Officer and as a member of the board of directors of Orbital Therapeutics, Inc. ("Orbital"), a biopharmaceutical company focused on RNA based medicines, from August 2024 until its acquisition by Bristol Myers Squibb (NYSE: BMY) in December 2025. Prior to joining Orbital, Mr. Philip served in roles of increasing responsibility at Spark Therapeutics, Inc. (formerly Nasdaq: ONCE) from May 2017 to August 2024, most recently as Chief Executive Officer. Prior to joining Spark Therapeutics, Mr. Philip served in various roles at Pfizer Inc. (NYSE: PFE) from November 2009 to October 2016. Mr. Philip currently serves on the board of directors of Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), Avalo Therapeutics, Inc. (Nasdaq: AVTX) and serves as Executive Chair of CREATE Medicines, Inc. Mr. Philip received a B.S. in Computer Information Systems from Drexel University.
- Saraswathy V. Nochur
-
Saraswathy V. Nochur自2025年2月起担任City Therapeutics，Inc.董事会成员。Nochur博士自2024年6月起担任监管事务和药物开发方面的独立顾问。此前，Nochur博士在Alnylam担任越来越多的职责，最近一次是在2021年1月至2024年5月期间担任首席多元化、公平和包容性官。在此之前，她曾于2005年5月至2020年12月担任Alnylam监管事务副总裁、监管事务高级副总裁和首席监管官，并担任Alnylam管理委员会成员。在加入Alnylam之前，Nochur博士曾在The Medicines Company担任监管事务方面日益重要的职责，最近担任监管事务副总裁。Nochur博士此前曾于2021年12月在Decibel Therapeutics, Inc.（纳斯达克：DBTX）的董事会任职，直至该公司于2023年9月被再生元制药公司（纳斯达克：REGN）收购，并于2021年3月至2024年11月被Marinus Pharmaceuticals, Inc.（纳斯达克：MRNS）收购。Nochur博士获得了印度孟买大学的微生物学和化学学士学位、微生物学硕士学位，以及麻省理工学院的生化工程博士学位。
Saraswathy V. Nochur has served as a member of City Therapeutics, Inc.'s board of directors since February 2025. Dr. Nochur has served as an independent consultant in regulatory affairs and drug development since June 2024. Previously, Dr. Nochur served in roles of increasing responsibility at Alnylam, most recently as Chief Diversity, Equity and Inclusion Officer from January 2021 to May 2024. Prior to that, she oversaw global regulatory affairs at Alnylam as Vice President of Regulatory Affairs, Senior Vice President of Regulatory Affairs, and Chief Regulatory Officer from May 2005 to December 2020, and she also served as a member of Alnylam's management board. Prior to joining Alnylam, Dr. Nochur served in roles of increasing responsibility in regulatory affairs at The Medicines Company, most recently as Vice President of Regulatory Affairs. Dr. Nochur previously served on the boards of directors of Decibel Therapeutics, Inc. (Nasdaq: DBTX) from December 2021 until its acquisition by Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) in September 2023 and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) from March 2021 to November 2024. Dr. Nochur received a B.S. in Microbiology and Chemistry, an M.S. in Microbiology from the University of Bombay, India, and a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology. - Saraswathy V. Nochur自2025年2月起担任City Therapeutics，Inc.董事会成员。Nochur博士自2024年6月起担任监管事务和药物开发方面的独立顾问。此前，Nochur博士在Alnylam担任越来越多的职责，最近一次是在2021年1月至2024年5月期间担任首席多元化、公平和包容性官。在此之前，她曾于2005年5月至2020年12月担任Alnylam监管事务副总裁、监管事务高级副总裁和首席监管官，并担任Alnylam管理委员会成员。在加入Alnylam之前，Nochur博士曾在The Medicines Company担任监管事务方面日益重要的职责，最近担任监管事务副总裁。Nochur博士此前曾于2021年12月在Decibel Therapeutics, Inc.（纳斯达克：DBTX）的董事会任职，直至该公司于2023年9月被再生元制药公司（纳斯达克：REGN）收购，并于2021年3月至2024年11月被Marinus Pharmaceuticals, Inc.（纳斯达克：MRNS）收购。Nochur博士获得了印度孟买大学的微生物学和化学学士学位、微生物学硕士学位，以及麻省理工学院的生化工程博士学位。
- Saraswathy V. Nochur has served as a member of City Therapeutics, Inc.'s board of directors since February 2025. Dr. Nochur has served as an independent consultant in regulatory affairs and drug development since June 2024. Previously, Dr. Nochur served in roles of increasing responsibility at Alnylam, most recently as Chief Diversity, Equity and Inclusion Officer from January 2021 to May 2024. Prior to that, she oversaw global regulatory affairs at Alnylam as Vice President of Regulatory Affairs, Senior Vice President of Regulatory Affairs, and Chief Regulatory Officer from May 2005 to December 2020, and she also served as a member of Alnylam's management board. Prior to joining Alnylam, Dr. Nochur served in roles of increasing responsibility in regulatory affairs at The Medicines Company, most recently as Vice President of Regulatory Affairs. Dr. Nochur previously served on the boards of directors of Decibel Therapeutics, Inc. (Nasdaq: DBTX) from December 2021 until its acquisition by Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) in September 2023 and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) from March 2021 to November 2024. Dr. Nochur received a B.S. in Microbiology and Chemistry, an M.S. in Microbiology from the University of Bombay, India, and a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.
- John Maraganore
-
John Maraganore是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、黑石生命科学的高级顾问、杰富瑞金融服务的高级顾问以及投资和风险投资公司RTW Investments，LP的执行合伙人。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（纳斯达克：PROK）董事会任职。Maraganore博士分别在芝加哥大学获得生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
John Maraganore one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago. - John Maraganore是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、黑石生命科学的高级顾问、杰富瑞金融服务的高级顾问以及投资和风险投资公司RTW Investments，LP的执行合伙人。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（纳斯达克：PROK）董事会任职。Maraganore博士分别在芝加哥大学获得生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
- John Maraganore one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago.
- Andrew Orth
-
Andrew Orth自2024年12月起担任City Therapeutics，Inc.总裁、首席执行官，并担任City Therapeutics，Inc.董事会成员。在加入City Therapeutics，Inc.之前，Orth先生曾于2021年5月至2023年8月担任Krystal Biotech, Inc.（纳斯达克：KRYS）的首席商务官，该公司是一家处于商业化阶段的全球性生物技术公司，负责领导该公司的全球商业战略和执行工作。此前，Orth先生曾于2016年至2021年在全球商业阶段的生物制药公司Alnylam（纳斯达克：ALNY）担任美国地区高级副总裁，在那里他为推出三种用于罕见疾病的基因药物以及在美国和欧洲建立Alnylam的商业基础设施做出了贡献。在加入Alnylam之前，Orth先生于2009年至2016年在Biogen Inc.（纳斯达克：BIIB）担任全球商业战略副总裁。在其职业生涯的早期，Orth先生曾在Russell Reynolds Associates Inc.、Genzyme Corp.（随后被赛诺菲 S.A.（纳斯达克：SNY）（“赛诺菲”）收购）、安进公司（纳斯达克：AMGN）和加州大学旧金山分校担任全球商业战略、商业运营、企业战略和财务等职务。Orth先生在威斯康星大学获得哲学和心理学学士学位，在康奈尔大学获得工商管理硕士学位。
Andrew Orth has served as City Therapeutics, Inc.'s President, Chief Executive Officer and as a member of City Therapeutics, Inc.'s board of directors since December 2024. Prior to joining City Therapeutics, Inc., Mr. Orth served as Chief Commercial Officer of Krystal Biotech, Inc. (Nasdaq: KRYS), a global, commercial stage biotechnology company, from May 2021 to August 2023, where he led its global commercial strategy and execution. Previously, Mr. Orth served as Senior Vice President, U.S. Region at Alnylam (Nasdaq: ALNY), a global commercial stage biopharmaceutical company, from 2016 to 2021, where he contributed to the launch of three genetic medicines for rare diseases and the build out of Alnylam's commercial infrastructure in the United States and Europe. Prior to Alnylam, Mr. Orth served as Vice President, Global Commercial Strategy at Biogen Inc. (Nasdaq: BIIB) from 2009 to 2016. Earlier in his career, Mr. Orth held positions in global commercial strategy, commercial operations, corporate strategy and finance at Russell Reynolds Associates Inc., Genzyme Corp. (subsequently acquired by Sanofi S.A. (Nasdaq: SNY) ("Sanofi"), Amgen Inc. (Nasdaq: AMGN) and the University of California, San Francisco. Mr. Orth received a B.S. in Philosophy and Psychology from the University of Wisconsin and an M.B.A. from Cornell University. - Andrew Orth自2024年12月起担任City Therapeutics，Inc.总裁、首席执行官，并担任City Therapeutics，Inc.董事会成员。在加入City Therapeutics，Inc.之前，Orth先生曾于2021年5月至2023年8月担任Krystal Biotech, Inc.（纳斯达克：KRYS）的首席商务官，该公司是一家处于商业化阶段的全球性生物技术公司，负责领导该公司的全球商业战略和执行工作。此前，Orth先生曾于2016年至2021年在全球商业阶段的生物制药公司Alnylam（纳斯达克：ALNY）担任美国地区高级副总裁，在那里他为推出三种用于罕见疾病的基因药物以及在美国和欧洲建立Alnylam的商业基础设施做出了贡献。在加入Alnylam之前，Orth先生于2009年至2016年在Biogen Inc.（纳斯达克：BIIB）担任全球商业战略副总裁。在其职业生涯的早期，Orth先生曾在Russell Reynolds Associates Inc.、Genzyme Corp.（随后被赛诺菲 S.A.（纳斯达克：SNY）（“赛诺菲”）收购）、安进公司（纳斯达克：AMGN）和加州大学旧金山分校担任全球商业战略、商业运营、企业战略和财务等职务。Orth先生在威斯康星大学获得哲学和心理学学士学位，在康奈尔大学获得工商管理硕士学位。
- Andrew Orth has served as City Therapeutics, Inc.'s President, Chief Executive Officer and as a member of City Therapeutics, Inc.'s board of directors since December 2024. Prior to joining City Therapeutics, Inc., Mr. Orth served as Chief Commercial Officer of Krystal Biotech, Inc. (Nasdaq: KRYS), a global, commercial stage biotechnology company, from May 2021 to August 2023, where he led its global commercial strategy and execution. Previously, Mr. Orth served as Senior Vice President, U.S. Region at Alnylam (Nasdaq: ALNY), a global commercial stage biopharmaceutical company, from 2016 to 2021, where he contributed to the launch of three genetic medicines for rare diseases and the build out of Alnylam's commercial infrastructure in the United States and Europe. Prior to Alnylam, Mr. Orth served as Vice President, Global Commercial Strategy at Biogen Inc. (Nasdaq: BIIB) from 2009 to 2016. Earlier in his career, Mr. Orth held positions in global commercial strategy, commercial operations, corporate strategy and finance at Russell Reynolds Associates Inc., Genzyme Corp. (subsequently acquired by Sanofi S.A. (Nasdaq: SNY) ("Sanofi"), Amgen Inc. (Nasdaq: AMGN) and the University of California, San Francisco. Mr. Orth received a B.S. in Philosophy and Psychology from the University of Wisconsin and an M.B.A. from Cornell University.
- Barry Greene
-
Barry Greene自2024年9月起担任City Therapeutics，Inc.董事会成员。Greene先生曾于2020年12月起担任生物制药公司Sage Therapeutics, Inc.（纳斯达克：SAGE）（“Sage”）的总裁兼首席执行官，直至该公司于2025年7月被Supernus Pharmaceuticals, Inc.（纳斯达克：SUPN）收购。在加入Sage之前，Greene先生曾于2007年至2020年9月担任Alnylam总裁，并于2003年9月至2020年12月担任首席运营官。在加入Alnylam之前，Greene先生曾担任Millennium Pharmaceuticals，Inc.的肿瘤学总经理。在其职业生涯的早期，Greene先生曾担任MediconSult.com，Inc.的执行副总裁兼首席商务官，阿斯利康 PLC（纳斯达克：AZN）的营销和客户服务副总裁兼战略整合副总裁，以及安德森咨询公司的合伙人。Greene先生目前在Karyopharm Therapeutics，Inc.（纳斯达克：KPTI）和Dyne Therapeutics, Inc.（纳斯达克：DYN）的董事会任职。他此前曾于2007年1月至2021年8月在Acorda Therapeutics, Inc.（纳斯达克：ACOR）董事会任职，并于2020年10月至2022年10月在BCLS Acquisition Corporation（纳斯达克：BLSA）董事会任职。Greene先生获得了匹兹堡大学工业工程学士学位，并在杜克大学医学院和Fuqua商学院完成了高级学者高管课程。
Barry Greene has served as a member of City Therapeutics, Inc.'s board of directors since September 2024. Mr. Greene served as President and Chief Executive Officer of Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage"), a biopharmaceutical company, from December 2020 until it was acquired by Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) in July 2025. Prior to joining Sage, Mr. Greene served as President of Alnylam from 2007 through September 2020 and as Chief Operating Officer from September 2003 to December 2020. Prior to joining Alnylam, Mr. Greene served as General Manager of Oncology at Millennium Pharmaceuticals, Inc. Earlier in his career, Mr. Greene served as Executive Vice President and Chief Business Officer at Mediconsult.com, Inc., Vice President of Marketing and Customer Services and Vice President, Strategic Integration at AstraZeneca PLC (Nasdaq: AZN), and Partner at Andersen Consulting. Mr. Greene currently serves on the board of directors of Karyopharm Therapeutics, Inc. (Nasdaq: KPTI) and Dyne Therapeutics, Inc. (Nasdaq: DYN). He previously served on the boards of directors of Acorda Therapeutics, Inc. (Nasdaq: ACOR) from January 2007 to August 2021 and BCLS Acquisition Corporation (Nasdaq: BLSA) from October 2020 to October 2022. Mr. Greene received a B.S. in Industrial Engineering from the University of Pittsburgh and completed the Senior Scholars executive program at Duke University's Medical School and Fuqua School of Business. - Barry Greene自2024年9月起担任City Therapeutics，Inc.董事会成员。Greene先生曾于2020年12月起担任生物制药公司Sage Therapeutics, Inc.（纳斯达克：SAGE）（“Sage”）的总裁兼首席执行官，直至该公司于2025年7月被Supernus Pharmaceuticals, Inc.（纳斯达克：SUPN）收购。在加入Sage之前，Greene先生曾于2007年至2020年9月担任Alnylam总裁，并于2003年9月至2020年12月担任首席运营官。在加入Alnylam之前，Greene先生曾担任Millennium Pharmaceuticals，Inc.的肿瘤学总经理。在其职业生涯的早期，Greene先生曾担任MediconSult.com，Inc.的执行副总裁兼首席商务官，阿斯利康 PLC（纳斯达克：AZN）的营销和客户服务副总裁兼战略整合副总裁，以及安德森咨询公司的合伙人。Greene先生目前在Karyopharm Therapeutics，Inc.（纳斯达克：KPTI）和Dyne Therapeutics, Inc.（纳斯达克：DYN）的董事会任职。他此前曾于2007年1月至2021年8月在Acorda Therapeutics, Inc.（纳斯达克：ACOR）董事会任职，并于2020年10月至2022年10月在BCLS Acquisition Corporation（纳斯达克：BLSA）董事会任职。Greene先生获得了匹兹堡大学工业工程学士学位，并在杜克大学医学院和Fuqua商学院完成了高级学者高管课程。
- Barry Greene has served as a member of City Therapeutics, Inc.'s board of directors since September 2024. Mr. Greene served as President and Chief Executive Officer of Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage"), a biopharmaceutical company, from December 2020 until it was acquired by Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) in July 2025. Prior to joining Sage, Mr. Greene served as President of Alnylam from 2007 through September 2020 and as Chief Operating Officer from September 2003 to December 2020. Prior to joining Alnylam, Mr. Greene served as General Manager of Oncology at Millennium Pharmaceuticals, Inc. Earlier in his career, Mr. Greene served as Executive Vice President and Chief Business Officer at Mediconsult.com, Inc., Vice President of Marketing and Customer Services and Vice President, Strategic Integration at AstraZeneca PLC (Nasdaq: AZN), and Partner at Andersen Consulting. Mr. Greene currently serves on the board of directors of Karyopharm Therapeutics, Inc. (Nasdaq: KPTI) and Dyne Therapeutics, Inc. (Nasdaq: DYN). He previously served on the boards of directors of Acorda Therapeutics, Inc. (Nasdaq: ACOR) from January 2007 to August 2021 and BCLS Acquisition Corporation (Nasdaq: BLSA) from October 2020 to October 2022. Mr. Greene received a B.S. in Industrial Engineering from the University of Pittsburgh and completed the Senior Scholars executive program at Duke University's Medical School and Fuqua School of Business.
- Ron Philip
-
Ron Philip自2024年7月起担任City Therapeutics，Inc.董事会成员。Philip先生于2024年8月至2025年12月被Bristol Myers Squibb（NYSE：BMY）收购之前，曾担任Orbital Therapeutics，Inc.（“Orbital”）的首席执行官和董事会成员，该公司是一家专注于基于RNA的药物的生物制药公司。在加入Orbital之前，Philip先生于2017年5月至2024年8月期间在星火治疗公司（前身为纳斯达克：ONCE）担任越来越多的职责，最近担任首席执行官。在加入星火治疗之前，Philip先生曾于2009年11月至2016年10月在辉瑞公司（纽约证券交易所代码：PFE）担任多个职务。Philip先生目前在Harmony Biosciences Holdings, Inc.（纳斯达克：HRMY）、Avalo Therapeutics, Inc.（纳斯达克：AVTX）的董事会任职，并担任CREATE Medicines，Inc.的执行主席。Philip先生获得德雷塞尔大学计算机信息系统学士学位。
Ron Philip has served as a member of City Therapeutics, Inc.'s board of directors since July 2024. Mr. Philip served as Chief Executive Officer and as a member of the board of directors of Orbital Therapeutics, Inc. ("Orbital"), a biopharmaceutical company focused on RNA based medicines, from August 2024 until its acquisition by Bristol Myers Squibb (NYSE: BMY) in December 2025. Prior to joining Orbital, Mr. Philip served in roles of increasing responsibility at Spark Therapeutics, Inc. (formerly Nasdaq: ONCE) from May 2017 to August 2024, most recently as Chief Executive Officer. Prior to joining Spark Therapeutics, Mr. Philip served in various roles at Pfizer Inc. (NYSE: PFE) from November 2009 to October 2016. Mr. Philip currently serves on the board of directors of Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), Avalo Therapeutics, Inc. (Nasdaq: AVTX) and serves as Executive Chair of CREATE Medicines, Inc. Mr. Philip received a B.S. in Computer Information Systems from Drexel University. - Ron Philip自2024年7月起担任City Therapeutics，Inc.董事会成员。Philip先生于2024年8月至2025年12月被Bristol Myers Squibb（NYSE：BMY）收购之前，曾担任Orbital Therapeutics，Inc.（“Orbital”）的首席执行官和董事会成员，该公司是一家专注于基于RNA的药物的生物制药公司。在加入Orbital之前，Philip先生于2017年5月至2024年8月期间在星火治疗公司（前身为纳斯达克：ONCE）担任越来越多的职责，最近担任首席执行官。在加入星火治疗之前，Philip先生曾于2009年11月至2016年10月在辉瑞公司（纽约证券交易所代码：PFE）担任多个职务。Philip先生目前在Harmony Biosciences Holdings, Inc.（纳斯达克：HRMY）、Avalo Therapeutics, Inc.（纳斯达克：AVTX）的董事会任职，并担任CREATE Medicines，Inc.的执行主席。Philip先生获得德雷塞尔大学计算机信息系统学士学位。
- Ron Philip has served as a member of City Therapeutics, Inc.'s board of directors since July 2024. Mr. Philip served as Chief Executive Officer and as a member of the board of directors of Orbital Therapeutics, Inc. ("Orbital"), a biopharmaceutical company focused on RNA based medicines, from August 2024 until its acquisition by Bristol Myers Squibb (NYSE: BMY) in December 2025. Prior to joining Orbital, Mr. Philip served in roles of increasing responsibility at Spark Therapeutics, Inc. (formerly Nasdaq: ONCE) from May 2017 to August 2024, most recently as Chief Executive Officer. Prior to joining Spark Therapeutics, Mr. Philip served in various roles at Pfizer Inc. (NYSE: PFE) from November 2009 to October 2016. Mr. Philip currently serves on the board of directors of Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), Avalo Therapeutics, Inc. (Nasdaq: AVTX) and serves as Executive Chair of CREATE Medicines, Inc. Mr. Philip received a B.S. in Computer Information Systems from Drexel University.
- Robert Nelsen
-
Robert Nelsen自2023年7月起担任City Therapeutics，Inc.董事会成员。Nelsen co先生于1986年创立了ARCH Venture Partners，这是一家专注于早期技术公司的风险投资公司，自1994年以来一直担任ARCH Venture Partners或其附属实体的董事总经理。内尔森先生目前在多家上市生物技术公司的董事会任职，包括Prime Medicine, Inc.（纳斯达克：PRME）、Sana Biotechnology, Inc.（纳斯达克：SANA）和Hua Medicine，Inc.（HKEX：2552）。Nelsen先生目前还在多家私营生物技术公司的董事会任职，此前曾在多家上市的生物技术和生物制药公司的董事会任职，包括2017年至2025年5月期间在VIR Biotechnology，Inc.（纳斯达克：VIR）、2019年至2025年5月期间在Lyell Immunopharma, Inc.TERM3（纳斯达克：LYEL）、2024年至2026年4月期间在Seaport Therapeutics，Inc.（Nasdaq 纳斯达克：SPTX）、2019年至2024年7月期间在Brii Biosciences Limited（HKEX：2137）、2020年至2023年9月期间在Neumora Therapeutics，Inc.（纳斯达克：NMRA）、Revolution Healthcare Acquisition Corp.（Revolution Healthcare Acquisition Corp.（Karuna Therapeutics, Inc.，Inc.（纳斯达克：KRTX）（后被百时美施贵宝收购）（后被百时美施贵宝收购）于2015年至2022年6月期间，Beam Therapeutics于2017年至2021年6月期间，TERM4，Inc.（TERM5：TERM6）（后被百时美施贵宝收购）于2018年至2021年6月期间。尼尔森先生在普吉特海湾大学获得经济学和生物学学士学位，在芝加哥大学获得工商管理硕士学位。
Robert Nelsen has served as a member of City Therapeutics, Inc.'s board of directors since July 2023. Mr. Nelsen co founded ARCH Venture Partners, a venture capital firm focused on early stage technology companies, in 1986, and has served as a Managing Director of ARCH Venture Partners or its affiliated entities since 1994. Mr. Nelsen currently serves on the boards of directors of several publicly traded biotechnology companies, including Prime Medicine, Inc. (Nasdaq: PRME), Sana Biotechnology, Inc. (Nasdaq: SANA), and Hua Medicine, Inc. (HKEX: 2552). Mr. Nelsen also currently serves on the boards of directors of a number of privately held biotechnology companies and previously served on the boards of directors of several publicly traded biotechnology and biopharmaceutical companies, including VIR Biotechnology, Inc. (Nasdaq: VIR) from 2017 to May 2025, Lyell Immunopharma, Inc. (Nasdaq: LYEL) from 2019 to May 2025, Seaport Therapeutics, Inc. (Nasdaq: SPTX) from 2024 to April 2026, Brii Biosciences Limited (HKEX: 2137) from 2019 to July 2024, Neumora Therapeutics, Inc. (Nasdaq: NMRA) from 2020 to September 2023, Revolution Healthcare Acquisition Corp. (Nasdaq: REVH) from 2021 to April 2022, Denali Therapeutics Inc. (Nasdaq: DNLI) from 2015 to June 2022, Beam Therapeutics from 2017 to June 2021, and Karuna Therapeutics, Inc. (Nasdaq: KRTX) (subsequently acquired by Bristol Myers Squibb) from 2018 to June 2021. Mr. Nelsen received his B.S. from the University of Puget Sound in Economics and Biology and his M.B.A. from the University of Chicago. - Robert Nelsen自2023年7月起担任City Therapeutics，Inc.董事会成员。Nelsen co先生于1986年创立了ARCH Venture Partners，这是一家专注于早期技术公司的风险投资公司，自1994年以来一直担任ARCH Venture Partners或其附属实体的董事总经理。内尔森先生目前在多家上市生物技术公司的董事会任职，包括Prime Medicine, Inc.（纳斯达克：PRME）、Sana Biotechnology, Inc.（纳斯达克：SANA）和Hua Medicine，Inc.（HKEX：2552）。Nelsen先生目前还在多家私营生物技术公司的董事会任职，此前曾在多家上市的生物技术和生物制药公司的董事会任职，包括2017年至2025年5月期间在VIR Biotechnology，Inc.（纳斯达克：VIR）、2019年至2025年5月期间在Lyell Immunopharma, Inc.TERM3（纳斯达克：LYEL）、2024年至2026年4月期间在Seaport Therapeutics，Inc.（Nasdaq 纳斯达克：SPTX）、2019年至2024年7月期间在Brii Biosciences Limited（HKEX：2137）、2020年至2023年9月期间在Neumora Therapeutics，Inc.（纳斯达克：NMRA）、Revolution Healthcare Acquisition Corp.（Revolution Healthcare Acquisition Corp.（Karuna Therapeutics, Inc.，Inc.（纳斯达克：KRTX）（后被百时美施贵宝收购）（后被百时美施贵宝收购）于2015年至2022年6月期间，Beam Therapeutics于2017年至2021年6月期间，TERM4，Inc.（TERM5：TERM6）（后被百时美施贵宝收购）于2018年至2021年6月期间。尼尔森先生在普吉特海湾大学获得经济学和生物学学士学位，在芝加哥大学获得工商管理硕士学位。
- Robert Nelsen has served as a member of City Therapeutics, Inc.'s board of directors since July 2023. Mr. Nelsen co founded ARCH Venture Partners, a venture capital firm focused on early stage technology companies, in 1986, and has served as a Managing Director of ARCH Venture Partners or its affiliated entities since 1994. Mr. Nelsen currently serves on the boards of directors of several publicly traded biotechnology companies, including Prime Medicine, Inc. (Nasdaq: PRME), Sana Biotechnology, Inc. (Nasdaq: SANA), and Hua Medicine, Inc. (HKEX: 2552). Mr. Nelsen also currently serves on the boards of directors of a number of privately held biotechnology companies and previously served on the boards of directors of several publicly traded biotechnology and biopharmaceutical companies, including VIR Biotechnology, Inc. (Nasdaq: VIR) from 2017 to May 2025, Lyell Immunopharma, Inc. (Nasdaq: LYEL) from 2019 to May 2025, Seaport Therapeutics, Inc. (Nasdaq: SPTX) from 2024 to April 2026, Brii Biosciences Limited (HKEX: 2137) from 2019 to July 2024, Neumora Therapeutics, Inc. (Nasdaq: NMRA) from 2020 to September 2023, Revolution Healthcare Acquisition Corp. (Nasdaq: REVH) from 2021 to April 2022, Denali Therapeutics Inc. (Nasdaq: DNLI) from 2015 to June 2022, Beam Therapeutics from 2017 to June 2021, and Karuna Therapeutics, Inc. (Nasdaq: KRTX) (subsequently acquired by Bristol Myers Squibb) from 2018 to June 2021. Mr. Nelsen received his B.S. from the University of Puget Sound in Economics and Biology and his M.B.A. from the University of Chicago.
- Barry Greene
-
Barry Greene，自2007年1月起成为本公司董事会成员。他目前担任Alnylam Pharmaceuticals Inc的总裁兼首席营运官。他于2003年9月进入 Alnylam，当时已有15年多的医疗行业从业和咨询经验。在进入Alnylam之前，他曾在Millennium Pharmaceuticals Inc担任肿瘤科总经理，领导公司的全球策略和肿瘤业务的开展，包括战略业务方向、执行力以及2003年年中VELCADE bortezomib的成功审批。在2001年进入 Millennium之前，他在Mediconsult.com担任执行副总裁间首席商务官。而更早前，他曾在AstraZeneca（原AstraMerck）担任市场部和客户服务部副总裁；曾担任战略整合部副总裁，负责AstraZeneca North American的并购；担任Andersen Consulting的合伙人，负责药/生物技术营销和销售活动。他曾担任 Regulus Therapeutics LLC 和Intercept Pharmaceuticals Inc的董事会成员。他在匹兹堡大学获得工业工程专业理学士学位，并是杜克大学富卡商学院的高级进修生。
Barry Greene has served on our board of directors since October 2020. Mr. Greene has served as the Chief Executive Officer of Sage Therapeutics Nasdaq: SAGE since December 2020. Mr. Greene has served on the boards of directors of Acorda Therapeutics (Nasdaq: ACOR) since 2008 and Karyopharm (Nasdaq: KPTI) since 2012. Mr. Greene has more than 30 years of experience in the healthcare, pharmaceutical and biotechnology industries, including his most recent role as President of Alnylam (Nasdaq: ALNY) from October 2003 to September 2020. Prior to Alnylam, Mr. Greene served as General Manager of Oncology at Millennium (Nasdaq: MLNM) from 2001 to 2003 where he led the company,s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of Velcade (bortezomib) in mid-2003. Prior to joining Millennium, Mr. Greene served as Executive Vice President and Chief Business Officer of Mediconsult from 1999 to 2000. Earlier in his career, Mr. Greene held various roles with AstraZeneca (Lon: AZN) from 1997 to 1999 and was a partner with Andersen Consulting (now Accenture (NYSE: CAN)) from 1986 to 1997. Mr. Greene earned a BS in industrial engineering from the University of Pittsburgh and served as Senior Scholar at Duke University, Fuqua School of Business. - Barry Greene，自2007年1月起成为本公司董事会成员。他目前担任Alnylam Pharmaceuticals Inc的总裁兼首席营运官。他于2003年9月进入 Alnylam，当时已有15年多的医疗行业从业和咨询经验。在进入Alnylam之前，他曾在Millennium Pharmaceuticals Inc担任肿瘤科总经理，领导公司的全球策略和肿瘤业务的开展，包括战略业务方向、执行力以及2003年年中VELCADE bortezomib的成功审批。在2001年进入 Millennium之前，他在Mediconsult.com担任执行副总裁间首席商务官。而更早前，他曾在AstraZeneca（原AstraMerck）担任市场部和客户服务部副总裁；曾担任战略整合部副总裁，负责AstraZeneca North American的并购；担任Andersen Consulting的合伙人，负责药/生物技术营销和销售活动。他曾担任 Regulus Therapeutics LLC 和Intercept Pharmaceuticals Inc的董事会成员。他在匹兹堡大学获得工业工程专业理学士学位，并是杜克大学富卡商学院的高级进修生。
- Barry Greene has served on our board of directors since October 2020. Mr. Greene has served as the Chief Executive Officer of Sage Therapeutics Nasdaq: SAGE since December 2020. Mr. Greene has served on the boards of directors of Acorda Therapeutics (Nasdaq: ACOR) since 2008 and Karyopharm (Nasdaq: KPTI) since 2012. Mr. Greene has more than 30 years of experience in the healthcare, pharmaceutical and biotechnology industries, including his most recent role as President of Alnylam (Nasdaq: ALNY) from October 2003 to September 2020. Prior to Alnylam, Mr. Greene served as General Manager of Oncology at Millennium (Nasdaq: MLNM) from 2001 to 2003 where he led the company,s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of Velcade (bortezomib) in mid-2003. Prior to joining Millennium, Mr. Greene served as Executive Vice President and Chief Business Officer of Mediconsult from 1999 to 2000. Earlier in his career, Mr. Greene held various roles with AstraZeneca (Lon: AZN) from 1997 to 1999 and was a partner with Andersen Consulting (now Accenture (NYSE: CAN)) from 1986 to 1997. Mr. Greene earned a BS in industrial engineering from the University of Pittsburgh and served as Senior Scholar at Duke University, Fuqua School of Business.
高管简历
中英对照 | 中文 | 英文- Keith Regnante
Keith Regnante自2020年2月起担任我们的首席财务官。在加入我们之前，Regnante先生于2016年8月至2020年1月担任Wave Life SciencesLtd.首席财务官2014年2月至2016年8月，雷南特先生担任全球生物制药公司Shire Pharmaceuticals或Shire的财务Vice President。在Shire任职期间，Regnante先生还曾在财务领导团队和研发领导团队任职。2013年9月至2014年2月，他担任ARIADPharmaceuticals，Inc.研发财务主管从1999年1月到2013年8月，Regnante先生在BiogenInc.担任多个财务职位，包括从2011年到2013年担任公司财务高级总监，从2008年到2011年担任全球研发财务高级总监，以及从1999年开始担任其他几个职位。在担任这些职务之前，Regnante先生在波士顿咨询集团（Boston Consulting Group）担任顾问。他持有Tufts University的经济学学士学位，以及the MIT Sloan School of Management的工商管理硕士学位。
Keith Regnante has served as Chief Financial Officer since February 2020. Prior to joining, from August 2016 to January 2020 Mr. Regnante served as Chief Financial Officer at Wave Life Sciences Ltd. From February 2014 to August 2016 Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, or Shire, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014 he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013 Mr. Regnante held multiple finance positions at Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013 Senior Director of Worldwide R&D Finance from 2008 to 2011 and several other positions dating back to 1999. Prior to these roles, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.- Keith Regnante自2020年2月起担任我们的首席财务官。在加入我们之前，Regnante先生于2016年8月至2020年1月担任Wave Life SciencesLtd.首席财务官2014年2月至2016年8月，雷南特先生担任全球生物制药公司Shire Pharmaceuticals或Shire的财务Vice President。在Shire任职期间，Regnante先生还曾在财务领导团队和研发领导团队任职。2013年9月至2014年2月，他担任ARIADPharmaceuticals，Inc.研发财务主管从1999年1月到2013年8月，Regnante先生在BiogenInc.担任多个财务职位，包括从2011年到2013年担任公司财务高级总监，从2008年到2011年担任全球研发财务高级总监，以及从1999年开始担任其他几个职位。在担任这些职务之前，Regnante先生在波士顿咨询集团（Boston Consulting Group）担任顾问。他持有Tufts University的经济学学士学位，以及the MIT Sloan School of Management的工商管理硕士学位。
- Keith Regnante has served as Chief Financial Officer since February 2020. Prior to joining, from August 2016 to January 2020 Mr. Regnante served as Chief Financial Officer at Wave Life Sciences Ltd. From February 2014 to August 2016 Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, or Shire, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014 he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013 Mr. Regnante held multiple finance positions at Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013 Senior Director of Worldwide R&D Finance from 2008 to 2011 and several other positions dating back to 1999. Prior to these roles, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.
- ジョンマラガノア
John Maraganore是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、Blackstone Life Sciences的高级顾问、杰富瑞金融服务的高级顾问以及RTW Investments，LP的执行合伙人，RTW Investments，LP均为一家投资和风险投资公司。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（纳斯达克：PROK）董事会任职。Maraganore博士分别获得了芝加哥大学的生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
John Maraganore one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago.- John Maraganore是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、Blackstone Life Sciences的高级顾问、杰富瑞金融服务的高级顾问以及RTW Investments，LP的执行合伙人，RTW Investments，LP均为一家投资和风险投资公司。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（纳斯达克：PROK）董事会任职。Maraganore博士分别获得了芝加哥大学的生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
- John Maraganore one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago.
- Sebastian Trousil
Sebastian Trousil是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的首席运营官。在加入City Therapeutics，Inc.之前，Trousil博士曾于2021年3月至2023年2月在投资公司RTW Investments，LP担任New Ventures的负责人。在此期间，Trousil博士还在2021年1月至2023年2月期间担任生物技术公司Yarrow Biotechnology，Inc.的首席运营官。Dr. Trousil co创立了Harbinger Health，Inc.，这是一家专注于早期癌症检测的液体活检公司，并在其早期发展期间担任领导角色。在其职业生涯的早期，Trousil博士曾在生命科学风险投资和公司建设公司Flagship Pioneering工作。Trousil博士获得奥地利维也纳大学药理学硕士学位，英国伦敦帝国理工学院药理学和癌症研究博士学位，并在哈佛医学院和麻省总医院完成博士后研究，获得Tosteson & Fund for Medical Discovery博士后奖学金。
Sebastian Trousil one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Chief Operating Officer since September 2023. Prior to joining City Therapeutics, Inc., Dr. Trousil served as Principal, New Ventures at RTW Investments, LP, an investment firm, from March 2021 to February 2023. During that time, Dr. Trousil also served as Chief Operating Officer of Yarrow Biotechnology, Inc., a biotechnology company, from January 2021 to February 2023. Dr. Trousil co founded Harbinger Health, Inc., a liquid biopsy company focused on early cancer detection, and served in leadership roles during its early development. Earlier in his career, Dr. Trousil worked at Flagship Pioneering, a life sciences venture capital and company building firm. Dr. Trousil received an M.Pharm. from the University of Vienna, Austria, and a Ph.D. in Pharmacology and Cancer Research from Imperial College London, England and completed postdoctoral research at Harvard Medical School and Massachusetts General Hospital, where he was awarded the Tosteson & Fund for Medical Discovery Postdoctoral Fellowship.- Sebastian Trousil是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的首席运营官。在加入City Therapeutics，Inc.之前，Trousil博士曾于2021年3月至2023年2月在投资公司RTW Investments，LP担任New Ventures的负责人。在此期间，Trousil博士还在2021年1月至2023年2月期间担任生物技术公司Yarrow Biotechnology，Inc.的首席运营官。Dr. Trousil co创立了Harbinger Health，Inc.，这是一家专注于早期癌症检测的液体活检公司，并在其早期发展期间担任领导角色。在其职业生涯的早期，Trousil博士曾在生命科学风险投资和公司建设公司Flagship Pioneering工作。Trousil博士获得奥地利维也纳大学药理学硕士学位，英国伦敦帝国理工学院药理学和癌症研究博士学位，并在哈佛医学院和麻省总医院完成博士后研究，获得Tosteson & Fund for Medical Discovery博士后奖学金。
- Sebastian Trousil one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Chief Operating Officer since September 2023. Prior to joining City Therapeutics, Inc., Dr. Trousil served as Principal, New Ventures at RTW Investments, LP, an investment firm, from March 2021 to February 2023. During that time, Dr. Trousil also served as Chief Operating Officer of Yarrow Biotechnology, Inc., a biotechnology company, from January 2021 to February 2023. Dr. Trousil co founded Harbinger Health, Inc., a liquid biopsy company focused on early cancer detection, and served in leadership roles during its early development. Earlier in his career, Dr. Trousil worked at Flagship Pioneering, a life sciences venture capital and company building firm. Dr. Trousil received an M.Pharm. from the University of Vienna, Austria, and a Ph.D. in Pharmacology and Cancer Research from Imperial College London, England and completed postdoctoral research at Harvard Medical School and Massachusetts General Hospital, where he was awarded the Tosteson & Fund for Medical Discovery Postdoctoral Fellowship.
- Andrew Orth
Andrew Orth自2024年12月起担任City Therapeutics，Inc.总裁、首席执行官，并担任City Therapeutics，Inc.董事会成员。在加入City Therapeutics，Inc.之前，Orth先生曾于2021年5月至2023年8月担任Krystal Biotech, Inc.（纳斯达克：KRYS）的首席商务官，该公司是一家处于商业化阶段的全球性生物技术公司，负责领导该公司的全球商业战略和执行工作。此前，Orth先生曾于2016年至2021年在全球商业阶段的生物制药公司Alnylam（纳斯达克：ALNY）担任美国地区高级副总裁，在那里他为推出三种用于罕见疾病的基因药物以及在美国和欧洲建立Alnylam的商业基础设施做出了贡献。在加入Alnylam之前，Orth先生于2009年至2016年在Biogen Inc.（纳斯达克：BIIB）担任全球商业战略副总裁。在其职业生涯的早期，Orth先生曾在Russell Reynolds Associates Inc.、Genzyme Corp.（随后被赛诺菲 S.A.（纳斯达克：SNY）（“赛诺菲”）收购）、安进公司（纳斯达克：AMGN）和加州大学旧金山分校担任全球商业战略、商业运营、企业战略和财务等职务。Orth先生在威斯康星大学获得哲学和心理学学士学位，在康奈尔大学获得工商管理硕士学位。
Andrew Orth has served as City Therapeutics, Inc.'s President, Chief Executive Officer and as a member of City Therapeutics, Inc.'s board of directors since December 2024. Prior to joining City Therapeutics, Inc., Mr. Orth served as Chief Commercial Officer of Krystal Biotech, Inc. (Nasdaq: KRYS), a global, commercial stage biotechnology company, from May 2021 to August 2023, where he led its global commercial strategy and execution. Previously, Mr. Orth served as Senior Vice President, U.S. Region at Alnylam (Nasdaq: ALNY), a global commercial stage biopharmaceutical company, from 2016 to 2021, where he contributed to the launch of three genetic medicines for rare diseases and the build out of Alnylam's commercial infrastructure in the United States and Europe. Prior to Alnylam, Mr. Orth served as Vice President, Global Commercial Strategy at Biogen Inc. (Nasdaq: BIIB) from 2009 to 2016. Earlier in his career, Mr. Orth held positions in global commercial strategy, commercial operations, corporate strategy and finance at Russell Reynolds Associates Inc., Genzyme Corp. (subsequently acquired by Sanofi S.A. (Nasdaq: SNY) ("Sanofi"), Amgen Inc. (Nasdaq: AMGN) and the University of California, San Francisco. Mr. Orth received a B.S. in Philosophy and Psychology from the University of Wisconsin and an M.B.A. from Cornell University.- Andrew Orth自2024年12月起担任City Therapeutics，Inc.总裁、首席执行官，并担任City Therapeutics，Inc.董事会成员。在加入City Therapeutics，Inc.之前，Orth先生曾于2021年5月至2023年8月担任Krystal Biotech, Inc.（纳斯达克：KRYS）的首席商务官，该公司是一家处于商业化阶段的全球性生物技术公司，负责领导该公司的全球商业战略和执行工作。此前，Orth先生曾于2016年至2021年在全球商业阶段的生物制药公司Alnylam（纳斯达克：ALNY）担任美国地区高级副总裁，在那里他为推出三种用于罕见疾病的基因药物以及在美国和欧洲建立Alnylam的商业基础设施做出了贡献。在加入Alnylam之前，Orth先生于2009年至2016年在Biogen Inc.（纳斯达克：BIIB）担任全球商业战略副总裁。在其职业生涯的早期，Orth先生曾在Russell Reynolds Associates Inc.、Genzyme Corp.（随后被赛诺菲 S.A.（纳斯达克：SNY）（“赛诺菲”）收购）、安进公司（纳斯达克：AMGN）和加州大学旧金山分校担任全球商业战略、商业运营、企业战略和财务等职务。Orth先生在威斯康星大学获得哲学和心理学学士学位，在康奈尔大学获得工商管理硕士学位。
- Andrew Orth has served as City Therapeutics, Inc.'s President, Chief Executive Officer and as a member of City Therapeutics, Inc.'s board of directors since December 2024. Prior to joining City Therapeutics, Inc., Mr. Orth served as Chief Commercial Officer of Krystal Biotech, Inc. (Nasdaq: KRYS), a global, commercial stage biotechnology company, from May 2021 to August 2023, where he led its global commercial strategy and execution. Previously, Mr. Orth served as Senior Vice President, U.S. Region at Alnylam (Nasdaq: ALNY), a global commercial stage biopharmaceutical company, from 2016 to 2021, where he contributed to the launch of three genetic medicines for rare diseases and the build out of Alnylam's commercial infrastructure in the United States and Europe. Prior to Alnylam, Mr. Orth served as Vice President, Global Commercial Strategy at Biogen Inc. (Nasdaq: BIIB) from 2009 to 2016. Earlier in his career, Mr. Orth held positions in global commercial strategy, commercial operations, corporate strategy and finance at Russell Reynolds Associates Inc., Genzyme Corp. (subsequently acquired by Sanofi S.A. (Nasdaq: SNY) ("Sanofi"), Amgen Inc. (Nasdaq: AMGN) and the University of California, San Francisco. Mr. Orth received a B.S. in Philosophy and Psychology from the University of Wisconsin and an M.B.A. from Cornell University.
- Tracy Zimmermann
Tracy Zimmermann自2024年5月起担任City Therapeutics，Inc.的首席科学官。在加入City Therapeutics，Inc.之前，Zimmermann博士曾在生物技术公司Generation Bio Co.（纳斯达克：GBIO）（被XOMA Royalty Corporation（纳斯达克：XOMA）收购）担任越来越多的职责，最近一次是在2020年11月至2024年1月担任首席开发官，此前曾在2018年10月至2020年11月担任临床前研究和转化生物学副总裁。此前，Zimmermann博士在Alnylam工作了15年，担任过跨RNAi平台开发和早期治疗项目的研究领导职务，在那里她为ONPATTRO、GIVLAARI和AMVUTTRA的开发做出了贡献。在她职业生涯的早期，Zimmermann博士曾在Variagenics，Inc.（随后与HYSEQ Pharmaceuticals Inc.合并，后者更名为Nuvelo，Inc.）担任高级科学家。Zimmermann博士获得了利哈伊大学的生物化学学士学位和科罗拉多大学博尔德分校的化学博士学位，并在哈佛医学院完成了博士后研究金。
Tracy Zimmermann has served as City Therapeutics, Inc.'s Chief Scientific Officer since May 2024. Prior to joining City Therapeutics, Inc., Dr. Zimmermann served in roles of increasing responsibility at Generation Bio Co. (Nasdaq: GBIO) (acquired by XOMA Royalty Corporation (Nasdaq: XOMA)), a biotechnology company, most recently as Chief Development Officer from November 2020 to January 2024, after serving as Vice President, Preclinical Research and Translational Biology from October 2018 to November 2020. Previously, Dr. Zimmermann spent 15 years at Alnylam, serving in research leadership positions spanning RNAi platform development and early stage therapeutic programs, where she contributed to the development of ONPATTRO, GIVLAARI and AMVUTTRA. Earlier in her career, Dr. Zimmermann served as a Senior Scientist at Variagenics, Inc. (subsequently merged with Hyseq Pharmaceuticals Inc., which was renamed Nuvelo, Inc.). Dr. Zimmermann received a B.S. in Biochemistry from Lehigh University and a Ph.D. in Chemistry from the University of Colorado Boulder and completed a postdoctoral fellowship at Harvard Medical School.- Tracy Zimmermann自2024年5月起担任City Therapeutics，Inc.的首席科学官。在加入City Therapeutics，Inc.之前，Zimmermann博士曾在生物技术公司Generation Bio Co.（纳斯达克：GBIO）（被XOMA Royalty Corporation（纳斯达克：XOMA）收购）担任越来越多的职责，最近一次是在2020年11月至2024年1月担任首席开发官，此前曾在2018年10月至2020年11月担任临床前研究和转化生物学副总裁。此前，Zimmermann博士在Alnylam工作了15年，担任过跨RNAi平台开发和早期治疗项目的研究领导职务，在那里她为ONPATTRO、GIVLAARI和AMVUTTRA的开发做出了贡献。在她职业生涯的早期，Zimmermann博士曾在Variagenics，Inc.（随后与HYSEQ Pharmaceuticals Inc.合并，后者更名为Nuvelo，Inc.）担任高级科学家。Zimmermann博士获得了利哈伊大学的生物化学学士学位和科罗拉多大学博尔德分校的化学博士学位，并在哈佛医学院完成了博士后研究金。
- Tracy Zimmermann has served as City Therapeutics, Inc.'s Chief Scientific Officer since May 2024. Prior to joining City Therapeutics, Inc., Dr. Zimmermann served in roles of increasing responsibility at Generation Bio Co. (Nasdaq: GBIO) (acquired by XOMA Royalty Corporation (Nasdaq: XOMA)), a biotechnology company, most recently as Chief Development Officer from November 2020 to January 2024, after serving as Vice President, Preclinical Research and Translational Biology from October 2018 to November 2020. Previously, Dr. Zimmermann spent 15 years at Alnylam, serving in research leadership positions spanning RNAi platform development and early stage therapeutic programs, where she contributed to the development of ONPATTRO, GIVLAARI and AMVUTTRA. Earlier in her career, Dr. Zimmermann served as a Senior Scientist at Variagenics, Inc. (subsequently merged with Hyseq Pharmaceuticals Inc., which was renamed Nuvelo, Inc.). Dr. Zimmermann received a B.S. in Biochemistry from Lehigh University and a Ph.D. in Chemistry from the University of Colorado Boulder and completed a postdoctoral fellowship at Harvard Medical School.
- Baisong Mei
Baisong Mei自2025年3月起担任City Therapeutics，Inc.的首席医疗官。此前，Dr. Mei于2022年7月至2024年12月期间，在Editas Medicine, Inc.（纳斯达克：EDIT）（“Editas”）担任执行副总裁兼首席医疗官，该公司是一家基因编辑公司，致力于为严重疾病开发变革性药物。在加入Editas之前，Dr. Mei于2017年1月至2022年7月在全球生物制药公司赛诺菲担任罕见病和罕见血液疾病领域的高级全球项目负责人。在加入赛诺菲之前，梅博士曾在Biogen Inc.担任血液学临床开发的治疗领域负责人。在其职业生涯的早期，梅博士曾在渤健和Bayer AG担任药物发现研究和化学、制造和控制开发方面的职务。梅博士获得中国蚌埠医科大学医学学士、中国武汉大学医学院医学硕士、托莱多大学生物化学与分子生物学博士学位，并在加州大学旧金山分校和加州大学伯克利分校担任博士后研究金。
Baisong Mei has served as City Therapeutics, Inc.'s Chief Medical Officer since March 2025. Previously, Dr. Mei served as Executive Vice President and Chief Medical Officer at Editas Medicine, Inc. (Nasdaq: EDIT) ("Editas"), a gene editing company developing transformative medicines for serious diseases, from July 2022 to December 2024. Prior to Editas, Dr. Mei served as Senior Global Project Head in Rare Disease and Rare Blood Disorders at Sanofi, a global biopharmaceutical company, from January 2017 to July 2022. Before joining Sanofi, Dr. Mei served as Therapeutic Area Head for Hematology Clinical Development at Biogen Inc. Earlier in his career, Dr. Mei held roles in drug discovery research and chemistry, manufacturing and controls development at Biogen and Bayer AG. Dr. Mei received a Bachelor of Medicine from Bengbu Medical University, China, a Master of Medicine from Wuhan University School of Medicine, China, and a Ph.D. in Biochemistry and Molecular Biology from the University of Toledo, and held postdoctoral fellowships at the University of California San Francisco and the University of California Berkeley.- Baisong Mei自2025年3月起担任City Therapeutics，Inc.的首席医疗官。此前，Dr. Mei于2022年7月至2024年12月期间，在Editas Medicine, Inc.（纳斯达克：EDIT）（“Editas”）担任执行副总裁兼首席医疗官，该公司是一家基因编辑公司，致力于为严重疾病开发变革性药物。在加入Editas之前，Dr. Mei于2017年1月至2022年7月在全球生物制药公司赛诺菲担任罕见病和罕见血液疾病领域的高级全球项目负责人。在加入赛诺菲之前，梅博士曾在Biogen Inc.担任血液学临床开发的治疗领域负责人。在其职业生涯的早期，梅博士曾在渤健和Bayer AG担任药物发现研究和化学、制造和控制开发方面的职务。梅博士获得中国蚌埠医科大学医学学士、中国武汉大学医学院医学硕士、托莱多大学生物化学与分子生物学博士学位，并在加州大学旧金山分校和加州大学伯克利分校担任博士后研究金。
- Baisong Mei has served as City Therapeutics, Inc.'s Chief Medical Officer since March 2025. Previously, Dr. Mei served as Executive Vice President and Chief Medical Officer at Editas Medicine, Inc. (Nasdaq: EDIT) ("Editas"), a gene editing company developing transformative medicines for serious diseases, from July 2022 to December 2024. Prior to Editas, Dr. Mei served as Senior Global Project Head in Rare Disease and Rare Blood Disorders at Sanofi, a global biopharmaceutical company, from January 2017 to July 2022. Before joining Sanofi, Dr. Mei served as Therapeutic Area Head for Hematology Clinical Development at Biogen Inc. Earlier in his career, Dr. Mei held roles in drug discovery research and chemistry, manufacturing and controls development at Biogen and Bayer AG. Dr. Mei received a Bachelor of Medicine from Bengbu Medical University, China, a Master of Medicine from Wuhan University School of Medicine, China, and a Ph.D. in Biochemistry and Molecular Biology from the University of Toledo, and held postdoctoral fellowships at the University of California San Francisco and the University of California Berkeley.